SCHEMBL1705017

SCHEMBL1705017

c1cnn(-c2ccc(CNC3CCC(Oc4ccc5cnccc5c4)CC3)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 3/20 0.46
ROCK2 O75116 1/20 0.46
IKBKB O14920 1/20 0.43
PRKCZ Q05513 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
DGAT2 Q96PD7 1/20 0.40
CXCR4 P61073 1/20 0.37
BRD4 O60885 1/20 0.36
CCNE1 P24864 3/20 0.35
CDK2 P24941 3/20 0.35
CDK1 P06493 1/20 0.35
FLT3 P36888 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
GAS6 Q14393 1/20 0.35
SYK P43405 1/20 0.35
CCNE2 O96020 1/20 0.35
CCNA2 P20248 1/20 0.35
CCNA1 P78396 1/20 0.35
CCNT1 O60563 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1705070 0.82 ROCK1 (0.53) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705674 0.82 ROCK1 (0.53) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705071 0.82 ROCK1 (0.53) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705839 0.82 ROCK1 (0.49) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705073 0.82 ROCK2 (0.49) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705680 0.81 ALDH1A1 (0.54) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705299 0.81 ALDH1A1 (0.54) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705684 0.80 IKBKB (0.51) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705995 0.79 ROCK1 (0.47) ROCK1ROCK2IKBKBPRKCZHRH3
SCHEMBL1705011 0.79 ROCK1 (0.49) ROCK1ROCK2IKBKBPRKCZHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US claimed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP claimed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
EP-2125746-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES Sanofi-Aventis (FR) 2009-12-02 EP disclosed
WO-2008077554-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives MYLK2, MYLK, MYLK3 ROCK1 8/4885ROCK2 6/4885IKBKB 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.